SCHEMBL3479751

SCHEMBL3479751

CN1CCN(c2ccc(Cl)c(Cl)c2)c2ccc(Br)cc2C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 14/20 0.48
SLC6A4 P31645 14/20 0.48
SLC6A3 Q01959 12/20 0.41
CYP2D6 P10635 6/20 0.41
KCNH2 Q12809 5/20 0.41
CYP2C19 P33261 2/20 0.41
MAPT P10636 2/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
BCL2 P10415 1/20 0.40
ALOX12 P18054 1/20 0.40
BID P55957 1/20 0.40
RAD51 Q06609 1/20 0.40
BCL2L1 Q07817 1/20 0.40
BCL2A1 Q16548 1/20 0.40
BCL2L2 Q92843 1/20 0.40
KMT2A Q03164 1/20 0.40
DRD2 P14416 1/20 0.39
DRD3 P35462 1/20 0.39
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3223749 0.86 POLB (0.42) MAPTALDH1A1ALOX12KMT2AKDM4E
SCHEMBL3480071 0.85 MAPT (0.50) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL3227337 0.84 SLC6A2 (0.48) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL3479634 0.82 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL3479697 0.82 SCN9A (0.37) SLC6A2SLC6A4SLC6A3CYP2D6MAPT
SCHEMBL3236889 0.81 ALDH1A1 (0.42) CYP2D6MAPTALDH1A1LMNAKMT2A
SCHEMBL3226442 0.81 SLC6A2 (0.45) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL3222825 0.81 SCN9A (0.40) LMNAKMT2ASIGMAR1
SCHEMBL3227778 0.81 HTR3A (0.51) SLC6A2SLC6A4SLC6A3DRD2DRD3
SCHEMBL3230352 0.80 MAPT (0.45) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D SLC6A2 28/4885SLC6A4 40/4885SLC6A3 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.